CML Treatment: Scenarios that Necessitate Switching Therapy
Jorge E. Cortes, MD, details clinical scenarios that indicate a need to switch therapies for patients with chronic myeloid leukemia.
This program was made possible with support from Novartis Pharmaceuticals.
Video content above is prompted by the following:
- In which scenarios do you consider switching CML therapies, and how do you approach that conversation with patients? How does the patient experience change when switching therapies?
Recent Videos
Related Content
